NMDA receptors in the basal ganglia.
作者信息
Ravenscroft P, Brotchie J
机构信息
Manchester Movement Disorders Laboratory, University of Manchester, UK.
出版信息
J Anat. 2000 May;196 ( Pt 4)(Pt 4):577-85. doi: 10.1046/j.1469-7580.2000.19640577.x.
Abstract
The basal ganglia consist of several interconnected nuclei located in the telecephalon, diencephalon and mesencephalon that are involved in a variety of motor and non-motor behavioural functions. Glutamate receptors play a major role in neurotransmission within the basal ganglia and are present in all nuclei of the basal ganglia. This review focuses on the contribution of the NMDA class of glutamatergic receptors to various movement disorders whose primary pathology lies within the basal ganglia and discusses how pharmacological manipulation of such receptors may be therapeutically useful.
摘要
相似文献
1
NMDA receptors in the basal ganglia.
J Anat. 2000 May;196 ( Pt 4)(Pt 4):577-85. doi: 10.1046/j.1469-7580.2000.19640577.x.
2
Prospects of glutamate antagonists in the therapy of Parkinson's disease.谷氨酸拮抗剂在帕金森病治疗中的前景。
Fundam Clin Pharmacol. 1998;12(1):4-12. doi: 10.1111/j.1472-8206.1998.tb00918.x.
3
Glutamatergic influences on the basal ganglia.谷氨酸能对基底神经节的影响。
Clin Neuropharmacol. 2001 Mar-Apr;24(2):65-70. doi: 10.1097/00002826-200103000-00001.
4
The pharmacology of tardive dyskinesias.迟发性运动障碍的药理学
Am J Psychiatry. 1973 Jan;130(1):82-6. doi: 10.1176/ajp.130.1.82.
5
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.药物多巴胺替代治疗和深部脑刺激治疗帕金森病引起的运动障碍中的谷氨酸能机制。
Prog Neurobiol. 2012 Jan;96(1):69-86. doi: 10.1016/j.pneurobio.2011.10.005. Epub 2011 Nov 3.
6
Roles of the M acetylcholine receptor in the basal ganglia and the treatment of movement disorders.M 乙酰胆碱受体在基底神经节中的作用及其在运动障碍治疗中的应用。
Mov Disord. 2019 Aug;34(8):1089-1099. doi: 10.1002/mds.27740. Epub 2019 Jun 18.
7
8
Dopamine-glutamate interactions in the basal ganglia.
Amino Acids. 1998;14(1-3):5-10. doi: 10.1007/BF01345235.
9
Neurochemical anatomy of movement disorders.运动障碍的神经化学解剖学
Neurol Clin. 1984 Aug;2(3):417-33.
10
Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia.
Ann Neurol. 1993 Oct;34(4):585-93. doi: 10.1002/ana.410340413.
引用本文的文献
1
Basal ganglia deep brain stimulation restores cognitive flexibility and exploration-exploitation balance disrupted by NMDA-R antagonism.基底神经节深部脑刺激可恢复因NMDA受体拮抗作用而破坏的认知灵活性和探索-利用平衡。
Nat Commun. 2025 May 28;16(1):4963. doi: 10.1038/s41467-025-60044-5.
2
Association between serum sodium and sporadic Parkinson's disease.血清钠与散发性帕金森病之间的关联。
Front Neurosci. 2025 Mar 25;19:1555831. doi: 10.3389/fnins.2025.1555831. eCollection 2025.
3
Moving to a non-dopaminergic approach for the treatment of OFF fluctuations in Parkinson's disease.转向非多巴胺能方法治疗帕金森病的“关”期波动。
Clin Park Relat Disord. 2025 Jan 27;12:100303. doi: 10.1016/j.prdoa.2025.100303. eCollection 2025.
4
Cerebellar and Striatal Implications in Autism Spectrum Disorders: From Clinical Observations to Animal Models.自闭症谱系障碍中的小脑和纹状体影响：从临床观察到动物模型。
Int J Mol Sci. 2022 Feb 18;23(4):2294. doi: 10.3390/ijms23042294.
5
Neuronal activity (c-Fos) delineating interactions of the cerebral cortex and basal ganglia.神经元活动（c-Fos）描绘大脑皮层和基底神经节的相互作用。
Front Neuroanat. 2014 Mar 26;8:13. doi: 10.3389/fnana.2014.00013. eCollection 2014.
6
Ketamine-induced oscillations in the motor circuit of the rat basal ganglia.氯胺酮诱导大鼠基底神经节运动回路的振荡。
PLoS One. 2011;6(7):e21814. doi: 10.1371/journal.pone.0021814. Epub 2011 Jul 29.
7
The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.神经炎症和犬尿氨酸途径在帕金森病中的作用。
Parkinsons Dis. 2011;2011:716859. doi: 10.4061/2011/716859. Epub 2011 Jun 3.
8
Increased cognitive functioning in symptomatic Huntington's disease as revealed by behavioral and event-related potential indices of auditory sensory memory and attention.行为学及与事件相关电位指标揭示有症状亨廷顿舞蹈病患者听觉感觉记忆和注意力方面认知功能增强
J Neurosci. 2008 Nov 5;28(45):11695-702. doi: 10.1523/JNEUROSCI.2659-08.2008.
9
Glutamate and GABA receptors and transporters in the basal ganglia: what does their subsynaptic localization reveal about their function?基底神经节中的谷氨酸和γ-氨基丁酸受体及转运体：它们的突触下定位对其功能有何揭示？
Neuroscience. 2006 Dec 1;143(2):351-75. doi: 10.1016/j.neuroscience.2006.09.019. Epub 2006 Oct 23.
10
Huntington's disease.亨廷顿舞蹈症
Mol Pathol. 2001 Dec;54(6):409-13. doi: 10.1136/mp.54.6.409.
本文引用的文献
1
Subunit- and site-specific pharmacology of the NMDA receptor channel.NMDA受体通道的亚基特异性和位点特异性药理学
Prog Neurobiol. 1999 Oct;59(3):279-98. doi: 10.1016/s0301-0082(99)00007-6.
2
3
Glutamate-triggered events inducing corticostriatal long-term depression.谷氨酸引发的诱导皮质纹状体长期抑制的事件。
J Neurosci. 1999 Jul 15;19(14):6102-10. doi: 10.1523/JNEUROSCI.19-14-06102.1999.
4
The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
Mov Disord. 1999 May;14(3):517-9. doi: 10.1002/1531-8257(199905)14:3<517::aid-mds1025>3.0.co;2-u.
5
Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.利血平处理大鼠中阻断含NR2B的NMDA受体的抗帕金森病作用
Exp Neurol. 1999 Jan;155(1):42-8. doi: 10.1006/exnr.1998.6963.
6
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.阻断谷氨酸能传递作为帕金森病运动障碍和运动波动的治疗方法。
Amino Acids. 1998;14(1-3):75-82. doi: 10.1007/BF01345246.
7
A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor.一条多巴胺/D1受体/蛋白激酶A/多巴胺和环磷酸腺苷调节的磷蛋白（32 kDa）/蛋白磷酸酶-1信号通路调节N-甲基-D-天冬氨酸受体的去磷酸化作用。
J Neurosci. 1998 Dec 15;18(24):10297-303. doi: 10.1523/JNEUROSCI.18-24-10297.1998.
8
Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model.
Eur J Pharmacol. 1998 Sep 4;356(2-3):101-4. doi: 10.1016/s0014-2999(98)00537-8.
9
Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A.缺乏NMDA受体亚基NR3A的小鼠中NMDA电流增加和树突棘密度增加。
Nature. 1998 May 28;393(6683):377-81. doi: 10.1038/30748.
10
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.金刚烷胺用于治疗帕金森病的运动障碍和运动波动。
Neurology. 1998 May;50(5):1323-6. doi: 10.1212/wnl.50.5.1323.
Zotero 插件